Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination
Arora, P.; Krueger, N.; Kempf, A.; Nehlmeier, I.; Sidarovich, A.; Graichen, L.; Moldenhauer, A.-S.; Winkler, M. S.; Schulz, S.; Jaeck, H.-M.; Stankov, M. V.; Behrens, G. M. N.; Poehlmann, S.; Hoffmann, M.
Show abstract
The delta variant of SARS-CoV-2, B.1.617.2, emerged in India and has subsequently spread to over 80 countries. B.1.617.2 rapidly replaced B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep increase in new infections, and a similar development is expected for other countries. Effective countermeasures require information on susceptibility of B.1.617.2 to control by antibodies elicited by vaccines and used for COVID-19 therapy. We show, using pseudotyping, that B.1.617.2 evades control by antibodies induced upon infection and BNT162b2 vaccination, although with lower efficiency as compared to B.1.351. Further, we found that B.1.617.2 is resistant against Bamlanivimab, a monoclonal antibody with emergency use authorization for COVID-19 therapy. Finally, we show increased Calu-3-lung cell entry and enhanced cell-to-cell fusion of B.1.617.2, which may contribute to augmented transmissibility and pathogenicity of this variant. These results identify B.1.617.2 as an immune evasion variant with increased capacity to enter and fuse lung cells.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The Omicron variant is highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 pandemic 98%
- SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination 96%
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity 96%
Similar papers in this journal
- SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination 98%
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 96%
- Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529 96%
Similar papers in this journal
- ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology 95%
- The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells 95%
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 95%
Similar papers in this journal
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 96%
- Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption 95%
- Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.